ESSA Pharma (NASDAQ:EPIX) Shares Cross Below Fifty Day Moving Average of $8.25

ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $8.25 and traded as low as $5.71. ESSA Pharma shares last traded at $6.08, with a volume of 178,467 shares trading hands.

ESSA Pharma Price Performance

The stock has a 50 day moving average price of $8.25 and a two-hundred day moving average price of $7.08. The firm has a market capitalization of $268.98 million, a price-to-earnings ratio of -10.30 and a beta of 1.62.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last issued its quarterly earnings data on Tuesday, February 13th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03. As a group, research analysts expect that ESSA Pharma Inc. will post -0.8 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ESSA Pharma

A number of institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets grew its stake in ESSA Pharma by 164.9% during the 4th quarter. BNP Paribas Financial Markets now owns 57,466 shares of the company’s stock worth $379,000 after purchasing an additional 35,771 shares in the last quarter. Rock Springs Capital Management LP grew its stake in ESSA Pharma by 2.1% during the 3rd quarter. Rock Springs Capital Management LP now owns 677,005 shares of the company’s stock worth $2,092,000 after purchasing an additional 13,688 shares in the last quarter. Finally, RTW Investments LP acquired a new position in ESSA Pharma during the 4th quarter worth $15,171,000. 75.12% of the stock is owned by institutional investors and hedge funds.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.